Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Obeticholic acid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1 | EXPERIMENTAL | Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration |
| Treatment Arm 2 | EXPERIMENTAL | Participants will receive OCA at dose level 2 along with linerixibat |
| Treatment Arm 3 | EXPERIMENTAL | Participants will receive OCA at dose level 1 along with linerixibat |
| Treatment Arm 4 | EXPERIMENTAL | Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration |
| Name | Type | Description |
|---|---|---|
| Obeticholic acid | DRUG | OCA will be administered |
| Linerixibat | DRUG | Linerixibat will be administered |
Inclusion Criteria: * Overtly healthy male or female participants 18 to 50 years of age inclusive, at the time of signing the informed consent * Body weight greater than (\>) 50 kilogram (kg) and body mass index (BMI) within the range 18.5 - 32 kilogram per meter square (kg/m\^2) (inclusive) * Capa...
Obeticholic acid is a small molecule being studied for pruritus, or itching. It is in Phase 1 clinical development for this dermatologic condition. The drug is investigational and has not been approved for this use.
Obeticholic acid is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this small molecule for pruritus.
Obeticholic acid is in Phase 1 clinical development for pruritus. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
Obeticholic acid has one completed clinical trial, NCT05133830, titled 'Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants.' This Phase 1 study enrolled 52 participants in the United States and was a controlled, randomized trial.
No, obeticholic acid and linerixibat are different drugs. They were studied together in a drug interaction trial, NCT05133830, which evaluated how they interact when administered to healthy adult participants.